drugset / Trial / NCT01386671

Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes

NCT01386671

Phase 3 Completed 203 enrolled Laboratorios Silanes S.A. de C.V.
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this study is to compare the efficacy and safety of Metformin Glycinate versus Metformin Hydrochloride in metabolic control and inflammatory mediators in Mexican type 2 diabetes patients, in a 12 months follow up.

Timeline

Start
2014-06
Primary completion
2016-02
Completion
2018-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metformin Small molecule 850 mg
Subject Metformin glycinate Unknown 1050.6 mg